Selection and optimization of hydrolysis conditions for the quantification of urinary metabolites of MDMA

Journal of Analytical Toxicology

Volumn 30, Issue 8, 2006, Pages 563-569

  Pirnay, Stephane O ^a   Abraham, Tsadik T ^a   Lowe, Ross H ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; ACID; AMPHETAMINE; BETA GLUCURONIDASE; HYDROCHLORIC ACID; METHAMPHETAMINE; UNCLASSIFIED DRUG;

ARTICLE; AUTOCLAVE; CHROMATOGRAPHY; CONTROLLED STUDY; ESCHERICHIA COLI; HELIX POMATIA; HUMAN; HYDROLYSIS; METABOLITE; TEMPERATURE; URINALYSIS;

ESCHERICHIA COLI; HELIX POMATIA;

EID: 33750171816     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/30.8.563     Document Type: Article

References (10)

1. L.H. Gold, G.F. Koob, and M.A. Geyer. Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J. Pharmacol. Exp. Ther. 247: 547-555 (1988).
2. L.J. Spanos and B.K. Yamamoto. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Pharmacol. Biochem. Behav. 32: 835-840 (1989).
3. D.E. Nichols. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new class: entactogens. J. Psychoactive Drugs 18: 305-313 (1986).
4. H.K. Lim and R.L. Foltz. Identification of metabolites of 3,4-(methylenedioxy)methamphetamine in human urine. Chem. Res. Toxicol. 2: 142-143 (1989).
5. R. de la Torre, M. Farre, P.N. Roset, C.H. Lopez, M. Mas, J. Ortuno, E. Menoyo, N. Pizarro, J. Segura, and J. Cami. Pharmacology of MDMA in humans. Ann. N.Y. Acad. Sci. 914: 225-237 (2000).
6. K.M. Jenkins, M.S. Young, C.R. Mallet, and A.A. Elian. Mixed-mode solid-phase extraction procedures for the determination of MDMA and metabolites in urine using LC-MS, LC-UV, or GC-NPD. J. Anal. Toxicol. 28: 50-58 (2004).
7. J. Ortuno, N. Pizarro, M. Farre, M. Mas, J. Segura, J. Cami, R. Brenneisen, and R. de la Torre. Quantification of 3,4- methylenedioxymethamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. J. Chromatogr. 723: 221-232 (1999).
8. M. Segura, J. Ortuno, M. Farre, J.A. McLure, M. Pujadas, N. Pizarro, A. Llebaria, J. Joglar, P.N. Roset, J. Segura, and R. de la Torre. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4- methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem. Res. Toxicol. 14: 1203-1208 (2001).
9. H. Helmlin, K. Bracher, D. Bourquin, D. Vonlanthen, and R. Brenneisen. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine HPLC-DAD and GC-MS. J. Anal. Toxicol. 20: 432-440 (1996).
10. S. Pirnay, T.T. Abraham, and M.A. Huestis. Sensitive gas chromatography/mass spectrometry method for the simultaneous measurement of MDEA, MDMA and metabolites, HMMA, MDA, and HMA in human urine. Clin. Chem., in press.